Summary of Phase 2 Trials
| Patient Type | N | Duration of study (not including run-in period) | Treatment arm/change in HbA1c from baseline | Reference |
|---|---|---|---|---|
| Type 2 | 51 | 3 months | • Inhaled insulin/0.7% | 12 |
| • Subcutaneous insulin/0.7% | ||||
| Type 2 | 62 | 3 months | • Oral agent/0.13% | 13 |
| • Oral agent plus inhaled insulin/2.28% | ||||
| Type 1 | 70 | 3 months | • Subcutaneous insulin (2–3 injections/day)/0.83% | 14 |
| • Inhaled insulin plus subcutaneous insulin (once daily)/0.64% |